Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial

Reisinger, EC; Tschismarov, R; Beubler, E; Wiedermann, U; Firbas, C; Loebermann, M; Pfeiffer, A; Muellner, M; Tauber, E; Ramsauer, K

Reisinger, EC (reprint author), Rostock Univ, Med Ctr, D-18055 Rostock, Germany.

LANCET, 2018; 392 (10165): 2718

Abstract

Background Chikungunya fever is an emerging viral disease and substantial threat to public health. We aimed to assess the safety, tolerability, and im......

Full Text Link